TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…

TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…

TS-038032 — A class of compounds possessing potent immunomodulatory activity, to enhance the protection of vaccines against infectious agents.

TS-015013 — Hydrogenase enzyme deficient bacterial strains that may be used as vaccines or attenuating agents for enteropathogenic diseases.